Related Experiment Video
Updated: May 21, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
[Metformin associated with lactic acidosis in treatment of type 2 diabetes]
Helle Holst1, Ebbe Eldrup, Nana Harriet Guldstad
1Klinisk Farmakologisk Afdeling, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 København NV, Denmark.
Abstract:
Metformin (MET) is the first-line agent in treatment of type 2 diabetes. However, MET has been associated with lactic acidosis (MALA), a potential but rare complication which has influenced treatment strategies in decades. Recently, guidelines have been changed in regards of age and heart failure and the contradiction of chronic renal impairment has been debated. This article identifies potential risk groups and situations that would benefit from a temporary interruption in the MET treatment.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Type II Diabetes II: Pathophysiology
Diabetes Mellitus: Type 2 and Gestational
Type I Diabetes III: Clinical Manifestations
Type II Diabetes I: Introduction
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
